Statement by Sung Poblete, PhD, RN, CEO of FARE, Regarding Xolair Receiving FDA Approval for Food Allergies
I am so excited to see that Xolair has been FDA-approved for food allergies. This is a massive win for our community. Patients will now have access to this new treatment opportunity. Thank you to the Genentech and Novartis teams, to the CoFAR sites who facilitated the phase three clinical trial, and most importantly to the brave patients who have volunteered to participate in the study.
Media Contact:
About FARE
FARE (Food Allergy Research & Education) is the leading nonprofit organization that empowers the food allergy patient across the journey of managing their disease. FARE delivers innovation by focusing on three strategic pillars—advocacy, research, and education—united by the through line of health equity. FARE’s initiatives accelerate the future of food allergy through effective policies and legislation, novel strategies toward prevention, diagnosis, and treatment, and building awareness and community. For more information, visit FoodAllergy.org.